Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 5/20 | 0.68 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367892 | 0.98 | GPBAR1 (0.97) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL7209087 | 0.95 | GPBAR1 (0.91) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL4184681 | 0.95 | GPBAR1 (0.90) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL3830421 | 0.95 | GPBAR1 (0.90) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL7205052 | 0.94 | GPBAR1 (0.88) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL4193765 | 0.92 | GPBAR1 (0.84) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL4177487 | 0.90 | GPBAR1 (0.82) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL4181812 | 0.89 | GPBAR1 (0.80) | GPBAR1LMNATSHRMCOLN3HSD17B10 | |
| SCHEMBL4174434 | 0.88 | GPBAR1 (0.78) | GPBAR1LMNATSHRHSD17B10USP2 | |
| SCHEMBL4186845 | 0.87 | PKM (0.76) | GPBAR1LMNATSHRUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250353906-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250276989-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4601696-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Flagship Pioneering Innovations VII, LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025136929-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250171512-A1 | FGF21 VARIANTS | SANOFI SA (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250163151-A1 | METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-05-22 | — | — | US | disclosed |
| US-20250140406-A1 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | INSIGHT MOLECULAR DIAGNOSTICS INC. | 2025-05-01 | — | — | US | disclosed |
| CN-113142245-B | Synergistic prevention and treatment of common thrips by Beauveria bassiana SB038 and spinetoram | 华南农业大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-113142244-B | Synergistic prevention and treatment of common thrips by Beauveria bassiana SB063 and spinetoram | 华南农业大学 | 2022-03-29 | — | — | CN | disclosed |
| US-11279702-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-20220040267-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | SANOFI SA (FR) | 2022-02-10 | — | — | US | disclosed |
| US-20220033401-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220023392-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | SANOFI SA (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276989-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | GPBAR1 21/4885LMNA 4674/4885TSHR 560/4885 |
| US-11279702-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | GPBAR1 132/4885LMNA 3464/4885TSHR 2028/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | GPBAR1 3545/4885LMNA 3368/4885TSHR 2619/4885 |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | GPBAR1 81/4885LMNA 3674/4885TSHR 576/4885 |
| US-20250353906-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | CD47, ACTB, ILK | GPBAR1 2731/4885LMNA 2209/4885TSHR 3706/4885 |
| US-20220033401-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | GPBAR1 132/4885LMNA 3464/4885TSHR 2028/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | GPBAR1 3545/4885LMNA 3368/4885TSHR 2619/4885 |
| US-20250163151-A1 | METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION | FABP2, EPCAM, ASGR1 | GPBAR1 1134/4885LMNA 3486/4885TSHR 3568/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | GPBAR1 3649/4885LMNA 926/4885TSHR 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.